Viridian Therapeutics, Inc.\DE (VRDN) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Viridian Therapeutics, Inc.\DE (VRDN): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 43/100 — a percentile rank of Viridian Therapeutics, Inc.\DE’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $2.2B |
| P / S | 30.2× |
| EV / EBITDA | -5.8× |
| Gross margin | 100.0% |
| Operating margin | -570.6% |
| Net margin | -544.1% |
| Return on equity | -50.5% |
| ROIC | -47.6% |
| Revenue growth | 23220.3% |
| Debt / equity | 0.5× |
| Dividend yield | 0.0% |
Is Viridian Therapeutics, Inc.\DE overvalued? P/S looks undervalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Viridian Therapeutics, Inc.\DE’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact